KR100624488B1 - A composition for preventing and treating obesity - Google Patents

Abstract

The invention ginseng (Panax ginseng CA Meyer), dermis (Citrus unshiu Marcovich), the upper lobe (and / or upper limbs) (Morus alba L.), uiyiin (Coix lachoryma-jobi Linne var. Ma-yuen S TAPF), Poria cocos ( Poria cocos W _OLF), jeoryeong (Polyporus umbellatus F _RIES), Acanthopanax (Acanthopanax sessiliflorum S _EEMAN), Eucommia (Eucommia ulmoides O _LIVER), sukjihwang (Rehmannia glutinosa L _IBOSCHITZ var. Purpurea M _AKINO , Lycium chinense M _ILLER , Angelica gigas Nakai, Cnidium officinale M _AKINO , Benincasa hispida C _OGNIAUX and Pinus densiflora S _IEBOLD et Z _UCCARINI It is to provide a composition, the composition of the present invention has no side effects and excellent in preventing and treating obesity, the composition of the present invention can be used for the prevention and treatment of obesity.

Herbal medicine, obesity, BIA, DXA, body fat reduction,

Description

A composition for preventing and treating obesity             

1 is a DXA planogram showing cut-points that determine arm and leg sites.

The present invention relates to a composition for preventing and treating obesity. In particular, the present invention relates to a composition for the prevention and treatment of obesity, containing a herbal ingredient as a main component.

The goal of preventing and treating obesity is to reduce body fat mass. In the rumors of the pathology, "此 人 必 數 食 甘味 而 多 肥 也 肥肥 者 令 人 이라고" is called, and Zhang Gaibin (張介賓) in Zhang, Yu-Kyung (張氏 類 經), "肥 者 多 濕"多 滯 ”said,“ 肥 者 味厚 助 陽 故 能 生 熱 ”and the obese people have a lot of 濕濕, and 熱熱 久 熱 化 熱 because the 兼 鬱 because of the fate of the fate have. Ju Jin-hyung was named "Shin-Gi-Gang" in the step-centering method. ), “肥 人 之”, “肥 人 之 運”, and Jinga-mo, “Shinsu-boncho” in “Shinsu-boncho”.痰 生 ”is called 氣虛 濕 痰 分 due to the lack of water distribution of the water is produced and 濕 生痰 and discussed the type of 滿 p. Based on the above theory, many herbal remedies have been applied to the treatment of obesity, and recently, pharmacological studies on the drugs constituting these prescriptions have revealed the effects on energy metabolism. The prescription used in the present invention was composed mainly of the sweet rice which was mainly studied as a conventional obesity treatment.

SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for preventing and treating obesity by activating the sympathetic nervous system, enhancing energy metabolism, inhibiting physical strength, inhibiting fat absorption, inhibiting cholesterol synthesis, and reducing fat loss and side effects when losing weight. will be.

The invention ginseng (Panax ginseng CA Meyer), dermis (Citrus unshiu Marcovich), the upper lobe (and / or upper limbs) (Morus alba L.), uiyiin (Coix lachoryma-jobi Linne var. Ma-yuen S TAPF), Poria cocos ( Poria cocos W _OLF), jeoryeong (Polyporus umbellatus F _RIES), Acanthopanax (Acanthopanax sessiliflorum S _EEMAN), Eucommia (Eucommia ulmoides O _LIVER), sukjihwang (Rehmannia glutinosa L _IBOSCHITZ var. Purpurea M _AKINO , Lycium chinense M _ILLER , Angelica gigas Nakai, Cnidium officinale M _AKINO , Benincasa hispida C _OGNIAUX and Pinus densiflora S _IEBOLD et Z _UCCARINI It provides a composition for the prevention and treatment of obesity.

Ginseng contains ginseng alkaloids, which enhances energy metabolism by activating preservation, viability, sympathetic nervous system and enhancing energy metabolism.

The dermis is a mature skin of tangerine or other coriander, with dry, windy expectoration.

It is known that the upper lobe and the upper limb have a dissipative effect of heat dissipation and hypoglycemic effect on the leaves and sprigs of mulberry and related plants.

Uiin is a seed that removes the seed of Yulmu, and it is known to have a dry mussew and diuretic effect.

Fukryeong is a fungal nucleus that has almost eliminated the outer layers of Bokryeong bacteria and is known to have diuretic, nourishing and sedative effects.

Low age is a fungal nucleus of the low-lying germ [ Grefolia umbellatus ]. It is known to have diuretic and blood pressure-lowering effects.

Ogapi is the bark of the roots, stems and branches of the Agapi tree or other related plants, and is known to have tonic and cardiac effects.

The larvae are bark of the larvae family and are known to have blood pressure lowering, sedative and analgesic effects.

Sukjihwang is processed from the roots of Jihwang or other similar plants, it is known to have nourishing tonic, hypoglycemic, cardiac, diuretic, antihistamine.

Goji berries are known to have dried fruit, dried, and nominal.

Angelica is known as the root of the true donkey, uterine function control, sedation, analgesic, diuretic, vitamin E deficiency treatment, antibacterial and hypoallergenic.

The uterus is the root of the uterus, and it is known to have antifungal, sedative, blood pressure lowering, vasodilation, antibacterial and antifungal vitamin E deficiency.

The confection is a seed of the fruit and is known to have diuretic, anti-inflammatory and expectorant effects.

Pine needles are the leaves of pine, and it is described as relieving consent and not hungry, and is known to reduce arteriosclerosis index.

Each of the above components may be extracted with water or a mixed solvent of water and lower alcohols to prepare the extract. As a mixed solvent of water and lower alcohols, 50% (v / v) of an aqueous alcohol solution (ethyl alcohol solution) Preference is given to using. Extraction may be performed by extracting each component separately, or by combining the respective components together.

Alternatively, the X of each component used in the present invention is already commercially available, it is also possible to purchase and use a commercially available one.

X-dle used in the present invention was used to buy X powder prepared by the drug department of Kyung Hee Medical Center.

In the present invention, Panax ginseng CA Meyer x 1-5 parts by weight, dermis ( Citrus unshiu Marcovich) x 3-20 parts, upper lobe (and / or upper limb) ( Morus alba L.) x 5-50 parts by weight, Coix lachoryma-jobi Linne var.ma -yuen S _TAPF 5-50 parts by weight, Poria cocos W _OLF x 3-20 parts, Heron ( Polyporus umbellatus F _RIES ) x 3-20 parts, Ogapi ( Acanthopanax sessiliflorum S _EEMAN ) x 2-10 parts by weight, tofu ( Eucommia ulmoides O _LIVER ) x 2-10 parts by weight, Rehmannia glutinosa L _IBOSCHITZ var. purpurea M _AKINO ) x 5-50 parts by weight, Lycium chinense M _ILLER x 3-20 parts, Angelica gigas Nakai x 2-10 parts, Cnidium officinale M _AKINO x 2-10 parts Boo, Benincasa hispida C _OGNIAUX x 2-10 parts by weight and pine needles ( Pinus densiflora S _IEBOLD et Z _UCCARINI ) are prepared by mixing. (These are all based on dry extract.)

The compositions of the present invention are formulated in the form of liquids, powders, tablets, capsules, syrups, or injectables which are added with excipients, additives, diluents, preservatives, etc., which are commonly used in the manufacture of foods or pharmaceuticals, and which are in the form of conventional formulations. can do.

The composition of the present invention may be administered by dividing 0.1-10g daily-several times a day.

Next, the present invention will be described in more detail as Examples and Experimental Examples.

Example 1

15 g of ginseng dry powder was added to 100 ml of water, stirred at 60 ° C. for 2 hours, and filtered. The filtrate is taken and the residue is extracted twice more in the same way and filtered. Combine the filtrates and evaporate the water to get ginseng extract.

Example 2

In the same manner as in Example 1, the dry powders of the dermis, upper leaf (or upper limb), Uiin, Fueryeong, Garyeong, Ogapi, Tofu, Sukjiwang, Gugija, Angelica, Cheongung, Dong confectionery, and pine needles were extracted with water, the extracts were combined, and water was evaporated. Get each X.

Example 3

15 g of ginseng dry powder was added to 100 ml of 50% (v / v) ethyl alcohol aqueous solution, stirred at 60 ° C. for 2 hours, and filtered. The filtrate is taken and the residue is extracted twice more in the same way and filtered. Combine the filtrates and evaporate the solvent to obtain ginseng extract.

Example 4

In the same manner as in Example 3, the dry powders of the dermis, upper leaf (or upper limb), Uiin, Fueryeong, Seong, Ogapi, Tofu, Sukjihwang, Gugija, Angelica, Cheongung, Dongjak and pine needles were extracted with water, the extracts were combined, and the solvent was evaporated. Get each X.

Example 5

Ginseng x 2 parts by weight, dermis x 8 parts by weight, upper leaf x 12 parts by weight, Euiin x 12 parts by weight, Boeryeong x 8 parts by weight, age x 8 parts by weight, Oga x 4 parts by weight, Tofu x 4 parts by weight, Sukjihwang x 12 parts by weight, wolfberry x 8 parts by weight, Angelica x 4 parts by weight, Cheongung x 4 parts by weight, Confectionery x 4 parts by weight, upper limbs x 4 parts by weight, and pine needles x 4 parts by weight Obtain the composition of the invention.

Example 6

Ginseng x 1 part by weight, dermis x 10 parts by weight, upper leaf x 10 parts by weight, Euiin x 10 parts by weight, Fuling x 15 parts by weight, age x 10 parts by weight, Ogapi x 5 parts by weight, Tofu The present invention by mixing X 5 parts by weight, Suk Hwang X 15 parts by weight, wolfberry X 10 parts by weight, Angelica X 5 parts by weight, Cheongung X 5 parts by weight, copper confectionery X 5 parts by weight, upper limbs X 5 parts by weight, and pine needles X 5 parts by weight To obtain a composition.

Formulation Example 1

1 g of the composition of Example 5 is mixed with 0.5 g of corn starch and sealed to prepare a powder.

Formulation Example 2

A capsule is prepared by mixing 1 g of the composition of Example 5 with 0.5 g of corn starch and 0.5 g of lactose and filling into a capsule.

Formulation Example 3

0.5 g of the composition of Example 5 is mixed with 0.2 g of corn starch and 0.5 g of lactose, a small amount of magnesium stearate and a small amount of talc and compressed into tablets.

Formulation Example 4

20 g of the composition of Example 6 and 20 g of isomerized sugar were dissolved in 100 ml of purified water and filled into a brown bottle to prepare a liquid.

Formulation Example 5

0.3 g of the composition of Example 5 is dissolved in 5 ml of distilled water for injection, filled into vials and sterilized to prepare an injection.

Experimental Example 1

The prescription of Table 1 (the same as that of Example 5, but the Xs are purchased from Kyung Hee Medical Center) is used in this experimental example.

1. Subject

Non-menopausal female patients with a body fat rate of more than 30% and under 25 years of age and under 55 years of age who have electrocardiograms, chest X-rays, kidneys, liver, thyroid dysfunction, diabetes, and those who have a change in body weight of more than 3 kg in the 2 months before the test The subjects were simple obese patients except smokers. Recruitment was through internet advertisement and newspaper advertisement. This study was approved by the Institutional Review Board of Kyung Hee Medical Center Hospital and received a written consent from all patients. A total of 50 people were recruited and 38 data except dropouts were used for statistical analysis.

2. Experimental method

1) Medication use

During the six weeks of the study, slim diets were given in three capsules a day at 30 minutes after breakfast, lunch and dinner.

2) Target Education

A dietary booklet was distributed to all patients and moderate exercise was recommended (eg, walking 30 minutes, 3 times a week). It was communicated to all patients that herbal medicine was used to treat obesity.

3) body measurement

Body weights were measured weekly to 0.1 kg and height to 0.5 cm. The waist circumference was measured by the WHO method and measured the circumference of the middle part of the lower rib and the pelvic iliac crest (up to 3 cm of the upper iliac spine) in the upright position. WH ratio was obtained by dividing the waist circumference by the hip circumference. In order to minimize the measurement error, the same measured by the same ruler was measured.

4) Bioelectrical impedance (BIA) measurement

Body weight, fat mass and muscle mass were measured up to 0.1 kg using Biospace's Body Composition Analyzer (Inbody 2.0) on the first day of the medication and the last morning of week 6.

5) Dual-Energy X-ray Absorptiometry (DXA) Measurement

Total body bone mineral content (TBBMC), total body fat (TBF), fat free mass (FFM, Body weight-total body fat) were measured by the whole body DXA scanner (DPX, GE Lunar, Madison). , WI, using software 3.6 version) was used to measure the first and last days of medication. Arms and legs were separated using specific anatomical boundaries (anterior view) (FIG. 1). The technical error of repeated measurements in the same subject is reported as TBBMC 0.9%, fat 3.4% and lean body fat 1.2%, respectively. Each bottle of 8L ethanol and distilled water disguised as fat and lean body tissues was scanned monthly and used as a marker for quality control. R-values measured during the clinical study were 1.255-1.258 (CV = 0.127%) and 1.367-1.371 (CV = 0.103%), respectively. In adults, a high correlation (r = 0.98) has been reported between limb muscle mass as measured by DXA and systemic muscle mass as measured by MRI.

6) blood test

The subjects' blood samples were collected on an empty stomach on the first and last morning of the medication. Total serum, triglyceride, and LDL cholesterol contents in serum were measured by an autoanalyzer using an enzymatic method. In addition, to evaluate the adverse effects caused by the medications, the tests of liver function levels such as AST, ALT, GGT and BUN, Creat, a measure of renal injury, were submitted to the Department of Clinical Pathology, Kyung Hee University Hospital.

3. Data Analysis

The mean value was expressed as mean ± S.D., The change was mean ± S.E., And the significance test was done by paired t-test, and p <0.05 or less was considered significant.

All statistical analyzes were performed using the SPSS 11.0 for windows program.

4. Age, weight and distribution of BMI

The average age of the subjects was 31.6 years, the minimum age was 24 years, and the highest age was 45 years. Average body weight was 81.33 ± 11.46 Kg. The results are shown in Table 2 below.

5. Changes in Body Composition Analysis

The results of the body composition analysis performed before and after six weeks of administration of the herbal composition (trade name “Cheap India”) according to the present invention are shown in Table 3 below.

Body weight was significantly decreased from 81.33 ± 11.46 kg to 78.42 ± 10.94 (p <0.01), and waist circumference was significantly decreased from 94.47 ± 7.15 to 91.39 ± 7.20 (p <0.01).

In BIA, FFM was significantly increased and TBF and Fat (%) were statistically significant (p <0.01). Overall, fat was decreased and body composition except fat was increased.

FFM measured on DXA tended to decrease from 47.29 ± 6.34 to 43.99 ± 17.38, but there was no statistical significance. TBF and Fat (%) were significantly decreased. TBBD did not change significantly.

6. Hematological analysis

Total cholesterol, total lipid, phospholipid and HDL cholesterol were significantly decreased, and trigliceride and LDL cholesterol were decreased, but there was no statistical significance. The results are shown in Table 4 below.

7. Safety Assessment

In the safety evaluation, the AST, ALT, and GGT levels, which are the measures of liver injury, were statistically significant and improved. The BUN and Creat test, which is a measure of renal injury, did not show statistically significant changes in the normal range, and thus no renal toxicity was observed. The results are shown in Table 5 below.

8. Evaluation

There was a significant decrease in both body fat percentage measured by BIA and body fat percentage measured by DXA during the 6-week study period. BIA showed a significant increase in lean body weight, but no significant change in DXA. In the case of weight loss, the decrease in body fat percentage tended to be higher than that of DXA, which may underestimate the decrease in body fat.

In evaluating the safety of the composition of the present invention, hepatic and nephrotoxicity did not appear, and in the case of hepatic enzyme level, it was found to be a great effect in the treatment of obesity in the clinic. Clinical studies across the country are considered necessary.

 The composition of the present invention had a significant decrease in both the body fat rate measured by the BIA method and the body fat rate measured by the DXA during the 6-week clinical study period. Therefore, the composition of the present invention can be usefully used for the prevention and treatment of obesity. .

Claims (4)

Ginseng (Panax ginseng CA Meyer), the dermis (Citrus unshiu Marcovich), mulberry (and / or upper limbs) (Morus alba L.), uiyiin (Coix lachoryma-jobi Linne var. Ma-yuen S TAPF), Poria cocos (Poria cocos W _OLF), jeoryeong (Polyporus umbellatus F _RIES), Acanthopanax (Acanthopanax sessiliflorum S _EEMAN), Eucommia (Eucommia ulmoides O _LIVER), sukjihwang (Rehmannia glutinosa L _IBOSCHITZ var. Purpurea M _AKINO , Lycium chinense M _ILLER , Angelica gigas Nakai, Cnidium officinale M _AKINO , Benincasa hispida C _OGNIAUX and Pinus densiflora S _IEBOLD et Z _UCCARINI Composition for the prevention and treatment of obesity. According to claim 1, Panax ginseng CA Meyer x 1-5 parts, dermis ( Citrus unshiu Marcovich) x 3-20 parts, upper lobe (and / or upper limb) ( Morus alba L.) x 5-50 Parts by weight, Coix lachoryma-jobi Linne var.ma -yuen S _TAPF 5-50 parts by weight, Poria cocos W _OLF x 3-20 parts by weight, age ( Polyporus umbellatus F _RIES ) x 3-20 Parts by weight, Acanthopanax sessiliflorum S _EEMAN x 2-10 parts by weight, tofu ( Eucommia ulmoides O _LIVER ) x 2-10 parts by weight, Rehmannia glutinosa L _IBOSCHITZ var. purpurea M _AKINO ) x 5-50 parts by weight, Lycium chinense M _ILLER x 3-20 parts, Angelica gigas Nakai x 2-10 parts, Cnidium officinale M _AKINO x 2-10 parts Part, Benincasa hispida C _OGNIAUX x 2-10 parts by weight and Pinus densiflora S _IEBOLD et Z _UCCARINI x 2-10 parts by weight of the composition for the prevention and treatment of obesity. A formulation containing the composition of claim 1 as a main component. 4. The formulation according to claim 3, wherein the formulation is in the form of a liquid, powder, tablet, capsule, syrup or injection.

Images